View Older Stories View More Recent Stories

Apr 7, 2020 06:45AM Merck (MRK) Receives Priority Review from FDA for Second Application for KEYTRUDA Based on Biomarker
Apr 7, 2020 06:45AM Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type
Apr 2, 2020 06:46AM Merck (MRK) Announces KEYTRUDA Significantly Improved PFS as First-Line Treatment for MSI-H or dMMR Colorectal Cancer
Apr 2, 2020 06:45AM Merck Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival as First-Line Treatment for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (d
Apr 2, 2020 06:30AM Merck to Hold First-Quarter 2020 Sales and Earnings Conference Call on April 28
Apr 1, 2020 04:00PM Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Apr 1, 2020 04:00PM Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Mar 30, 2020 06:11AM Merck (MRK) Reports Investigational Drug Vericiguat Significantly Reduced the Risk of Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death
Mar 28, 2020 10:00AM Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with A
Mar 25, 2020 05:00PM Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response
Mar 22, 2020 11:52AM Merck Donates a Half a Million Masks to Support COVID-19 Emergency Response in New York City
Mar 20, 2020 05:01PM Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
Mar 17, 2020 06:46AM Merck (MRK) Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant
Mar 17, 2020 06:45AM Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough
Mar 13, 2020 08:00AM EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Mar 12, 2020 05:59AM Merck (MRK), AstraZeneca (AZN) Report Update on Phase 3 GY004 for Cediranib & LYNPARZA (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
Mar 12, 2020 03:00AM Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
Mar 4, 2020 06:45AM Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents that Block Multiple Stages of the Lifecycle of the Parasite
Mar 3, 2020 02:00PM MilliporeSigma's New LANEXO™ System to Improve Scientists' Productivity in the Lab
Mar 2, 2020 06:45AM Merck Announces New Data from Broad HIV Program at CROI 2020
Mar 2, 2020 06:31AM Merck's (MRK) KEYTRUDA Significantly Improved PSF Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory cHL
Mar 2, 2020 06:30AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Feb 27, 2020 06:45AM Merck to Present at the Cowen Health Care Conference
Feb 18, 2020 07:17PM Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule
Feb 14, 2020 11:20AM ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification
Feb 12, 2020 06:52AM Merck's (MRK) KEYTRUDA in Combination with Chemotherapy Met Primary Endpoint of PFS as First-Line Treatment for mTNBC
Feb 12, 2020 06:45AM Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNB
Feb 5, 2020 06:47AM Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results
Feb 5, 2020 06:46AM Merck (MRK) Announces Spinoff of Women�s Health, Trusted Legacy Brands and Biosimilars Products
Feb 5, 2020 06:45AM Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilars Products into New Company (“NewCo”)
Feb 3, 2020 06:46AM Merck (MRK) Reports FDA Acceptance for sNDA Review for RECARBRIO (imipenem, cilastatin, and relebactam)
Feb 3, 2020 06:45AM FDA Accepts For Review Supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bac
Jan 31, 2020 04:08PM Merck (MRK) Reports Election of Dr. Christine Seidman and Kathy Warden to Board
Jan 31, 2020 04:05PM Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors
Jan 28, 2020 01:21PM Merck Announces Second-Quarter 2020 Dividend
Jan 28, 2020 02:00AM Lung Cancer Study Shows Barriers in Patient Access to Care in Europe
Jan 27, 2020 06:47AM Merck (MRK) Reports FDA Approval of DIFICID (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older
Jan 27, 2020 06:45AM FDA Approves Merck’s DIFICID® (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older
Jan 21, 2020 06:55AM FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
Jan 18, 2020 09:00AM Significant Study on Veterinary Wellbeing Reveals Importance of Continued Focus on Personal and Professional Health and Wellbeing Among Veterinarians
Jan 16, 2020 08:34AM Merck (MRK) Completes Acquisition of ArQule (ARQL)
Jan 16, 2020 08:34AM Merck Completes Acquisition of ArQule
Jan 8, 2020 04:33PM Merck (MRK) Announces FDA Approved its KEYTRUDA for Patients With BCG-Unresponsive, High-Risk, NMIBC With CIS With or Without Papillary Tumors
Jan 8, 2020 04:31PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Inel
Jan 6, 2020 04:06PM Merck's (MRK) KEYTRUDA in Combination with Chemotherapy Significantly Improved PFS Compared to Chemotherapy Alone as First-Line Treatment for ES-SCLC
Jan 6, 2020 04:05PM Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small
Jan 6, 2020 07:00AM BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Jan 6, 2020 06:31AM Merck (MRK) Announces Strategic Oncology Collaboration with Taiho and Astex
Jan 6, 2020 06:30AM Merck Establishes Strategic Oncology Collaboration with Taiho and Astex
Jan 3, 2020 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2019 Sales and Earnings Conference Call on February 5
View More Recent Stories View Older Stories